Search
Research
Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody testPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
Complex Experiences of Gender AffirmationThis project explores the mental health and support needs of Australians with complex experiences of gender-affirmation.
Research
Compound Repurposing Into Novel Therapeutics In COVID-19 At risk Lungs (CRITICAL Study)Anthony Christopher David Ingrid Shannon Thomas Kicic Blyth Martino Laing Simpson Iosifidis BSc (Hons) PhD MBBS (Hons) DCH FRACP FRCPA PhD BSc PhD
Research
CONNECT-CP (A Clinical Research Program to Improve Connection, Access and Translation of Evidence in Cerebral Palsy)CONNECT-CP aims to diagnose cerebral palsy (CP) earlier and ensure all children in Western Australia (WA) have access to early assessment and support.
Research
Core Competencies and Reporting Guidelines for Co-research with Adolescents (The C3 Study)The C3 Study is an exploration into best practice around co-research with youth consumers being led by the Adolescent Health and Wellbeing Team at The Kids Research Institute Australia, who are based in Adelaide.
Explore some of the frequently asked questions that The C3 Study receives.
Research
COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years oPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
CP Movetime: A wearable sensor and user interface to reduce sedentary behaviours in non-ambulant children and youth with cerebral palsyCP Movetime aims to establish and test a technology-based application to improve health outcomes by monitoring device measured sedentary behaviours in non-ambulant children and youth with cerebral palsy.
Research
DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosisSensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis.
Research
Defining the cellular immune response to vaccines for enhanced protection from invasive pneumococcal diseasePeter Lea-Ann Ruth Richmond Kirkham Thornton MBBS MRCP(UK) FRACP PhD PhD Head, Vaccine Trials Group Co-Head, Bacterial Respiratory Infectious Disease